Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

WAYNE, N.J. and EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was stopped early following a planned interim analysis by the independent Data Monitoring Committee (DMC). The trial was sponsored by the National Cancer Institute (NCI) and led by the Eastern Cooperative Oncology Group (ECOG) under a Clinical Trials Agreement between NCI and Bayer and Onyx. The DMC concluded that the study would not meet the primary endpoint of improved overall survival among patients receiving Nexavar in combination with the chemotherapeutic agents carboplatin and paclitaxel versus patients receiving placebo plus the chemotherapeutic agents. The treatment effect was comparable in each arm. The DMC also reported that there were no unexpected serious side effects, though the final analysis of the data will occur per protocol and statistical analysis plan.

Bayer and Onyx will further review the findings of this analysis to determine what, if any, impact these data might have on other ongoing Nexavar melanoma trials. Data from this study are expected to be presented at an upcoming scientific meeting.

"We're disappointed with the results of the study and that the therapy did not bring benefit to patients with melanoma, a historically difficult tumor to treat," said Todd Yancey, M.D., vice president of clinical development at Onyx. "Onyx and Bayer remain committed to our broad clinical program to investigate the potential of Nexavar in a wide range of cancers, and we intend to build upon the success of Nexavar in our approved indications in hepatocellular carcinoma (liver cancer) and advanced renal cell carcinoma (kidney cancer
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... -- At the upcoming Radiological Society of North ...al Philips Electronics ( PHG, AEX: PHI) will demon...matics solutions designed to directly address the ...vering meaningful imaging innovations that reflect... upgradability. This focus will enable Philips to...
(Date:11/25/2009)...RNewswire/ -- Praxis Electronic Medical Records re...y of Family Physicians, (AAFP) Family Practice Man...r improving medical quality, health maintenance, a...timulus legislation. Praxis also ranked #1 among d...in determining their salary. Finally, Praxis also ...
(Date:11/25/2009)...wswire-FirstCall/ -- Heska Corporation ( HSKA); ("...ic and specialty products to the veterinary indust...ics Corporation for the supply of blood gas produc...arket. ,, (Logo: http://www.newscom.com/cg...oche share the same passion for innovating in the ...
Breaking Medicine Technology:Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Tianyin Pharmaceutical Co to Present at the Rodman 26 Renshaw Annual Global Investment Conference on September 11 at 10 3A50 am ET 13735 1Tianyin Pharmaceutical Co to Present at the Rodman 26 Renshaw Annual Global Investment Conference on September 11 at 10 3A50 am ET 13735 2Tianyin Pharmaceutical Co to Present at the Rodman 26 Renshaw Annual Global Investment Conference on September 11 at 10 3A50 am ET 13735 3Video 3A CVS pharmacy and MinuteClinic Encourage Americans to Protect Themselves Early With a Seasonal Flu Shot 55682 1Video 3A CVS pharmacy and MinuteClinic Encourage Americans to Protect Themselves Early With a Seasonal Flu Shot 55682 2Video 3A CVS pharmacy and MinuteClinic Encourage Americans to Protect Themselves Early With a Seasonal Flu Shot 55682 3Video 3A CVS pharmacy and MinuteClinic Encourage Americans to Protect Themselves Early With a Seasonal Flu Shot 55682 4IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests 55679 1IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests 55679 2
...one) decreased the risk of,stroke by 34% in patien...dy adequately treated by antithrombot...ts of a,post-hoc analysis of the data from the ATH...al update session of the European Society of Cardi...results from the landmark,ATHENA study have shown ...
...nch Progress and Adlea Reg...l Today at 11:30 am ET, SOUTH SAN FRANCISCO, Cali...ed today that the company will restructure,operati...development to,accelerate its transition to a spec...company also provided updates on Zingo launch prog...
Other Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5
(Date:11/27/2009)... Three new interactive anatomy education app...ins expand health sciences learning opportunities ... Durham, NC (Vocus) November 27, 2009 -- Modali...WW), a division of Wolters Kluwer Health, today an...ation apps on the App Store. Clemente’s Anat...
(Date:11/26/2009)...big or too heavy can lead to strains or worse , ...ere may be nothing wrong with stuffing your turkey...e same thing with your suitcase as you pack for ho...ated in 2008 in U.S. hospital emergency rooms, doc...s for luggage-related injuries, such as muscle str...
(Date:11/26/2009)... Benton Communications announces a highly ef...for retailers struggling to make an economic recov...6, 2009 -- Flu fears is the type of challenge that...room, according to Dr. David Benton, business grow...s growth system – The Rfactor Intensive . ...
(Date:11/25/2009)...ALGARY,Nov.25/PRNewswire/-SentinelleMedicalInc.,al...oilsandsoftwareandCalgaryScientificInc.,aleadingpr...dawebversionofAegis(TM)Breast4DAdvancedVisualizati...ttrulyzero-footprintWebclientbasedmedicalimagingof...atformallowsforzero-footprintaccess-requiringnosof...
(Date:11/25/2009)...ANCISCO, Nov. 25 The Bay Area Air ...s first Winter Spare the Air Aler...rning wood, manufactured firelogs or any other sol...till weather will contribute to unhealthy air qual...cer of the Air District. "We,re asking Bay Area re...
Breaking Medicine News(10 mins):Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2
...g babies unattended in standard car safety seats c...ms//, according to a recent study. A study co...esearchers at the University of Auckland in New Ze...g of babies in car seats could narrow their upper ...
...le drug for multiple complaints like cholesterol, ...ng designed at Dr Reddy’s the Hyderabad-based labo...e up with a combination of four drugs — a choleste...troke by 60 per cent. It will be available in the ...
... find a combination of healthy and tasty when we d... us any option of low calorie foods//. Mostly...ies we consume each meal, as we depend on the chef...e are becoming more health conscious. At the same ...
...breast cancer patients who are still young, and ha...ait for the stipulated //two years, post-treatment... Previously, young breast cancer patients wer...ersity of Western Australia said, 'For women with ...
... cancer screening has proven helpful to abort almo...ever researchers opine that such //screening unnec...adiation. NHS offers regular screening tests ... women under the age of 50 as well, it would poten...
...y conducted by Minnesota students have revealed th...ng themselves daily are more prone to develop eati...ealthy crash diets. In spite of dieting, they end ...it, and use diet pills in order to lose weight. Pr...
Other Medicine News:Health News:Poly-pill – A Single Drug For Multiple Complaint 2Health News:Are You Health-Conscious or Tongue- Conscious? 2
... PSE Power Supply . The digital 200 V/2000 mA PSE... 10 mA increments. • It is possible to run up...t 55°C. Features: Direct reading of programme... time • Voltage, mA and timer adjustable duri...
PowerPac HV Power Supply
... PRODUCT SPECIFICATIONS Form: Granular, free-flowi...Gel Point (3%): less than or equal to 35C Reme...trength (3%): greater than or equal to 300 gm/... less than or equal to 0.10% DNase: Passes tes...
...ride (Cl) ≤ 500 mg/kg sulfate (SO 4 ) ≤... ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ≤ 5 m...04; 50 mg/kg Mg ≤ 50 mg/kg Mn ≤ 5 mg/k...04; 5 mg/kg Zn ≤ 5 mg/kg Special grade: for ...
Medicine Products: